

MINUTES

Utah Department of Health Drug Utilization Review Board

Thursday, August 10, 2017 7:15 a.m. to 8:30 a.m. Cannon Health Building Room 125

Board Members Present:

Ben Berrett, Pharm.D.

Jennifer Brinton, M.D., Board Chair

Eric Cannon, Pharm.D., FAMCP

Neal Catalano, Pharm.D.

Steve Lore, M.D.

Kim Michelson, D.D.S.

Kumar Shah, M.Sc., P.Eng.

Keith Tolman, M.D.

Sharon Weinstein, M.D.

Board Members Excused:

Aesha Drozdowski, Pharm.D.

Susan Siegfreid, M.D

Katherine Smith, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Sue Leong, RPh., Pharmacy Director

Robyn Seely, Pharm.D., DUR Manager

Bryan Larson, Pharm.D., P&T Manager

Andrea Rico, CPhT

Alyssa Pitts, R.N., P.A.

Heather Santacruz, R.N., PA

University of Utah Drug Regimen Review Center Staff:

Joanita Lake, B.Pharm, MSc EBHC

Joanne LaFleur, Pharm.D.

Elena Martinez Alondo, Pharm.D.

Vicki Frydrych, Pharm.D.

Valarie Gonzales, Pharm.D.

Other Individuals Present

Jennifer Oh. SelectHealth

Deb Profant, Ph.D. Jazz Pharmaceuticals
Kevin Kassaban, Pharm.D., Shire
Alan Baily, PfizerName, Company
Russell Frandsen, Legislative Fiscal Analyst
Lori Howarth, Bayer

Lou Blad, Pfizer
Charissa Anne, Johnson & Johnson
Laura Britton, HealthyU
Don McCaffy, Vertex

Meeting conducted by: Board Chair

- 1. **Welcome & Housekeeping:** Robyn Seely opened the meeting and reminded everyone to sign the rosters. Jennifer Brinton nominated Keith Tolman via email for DUR Board Chair. Motion to approve board chair nomination, all in favor.
- 2. **Review and Approval of July Minutes:** Keith Tolman requested board chair nomination Holly Gurgle added to July's meeting minutes and will be re-presented in the September DURB meeting for approval.

- 3. **Follow up regarding selected Prescriber Continuing Education Requirements:** Sue Leong presented information regarding the CE information for physicians and pharmacists.
- 4. **Initial Prior Authorization on New NDCs:** Robyn Seely and Sue Leong presented PA criteria for Newly Marketed Drugs. Sharon Weinstein motioned to adopt PA criteria for newly marketed drugs, Eric Cannon seconded. Unanimous Approval.

5. Benzodiazepines & ADD/ADHD Therapies:

- **a. Information:** Joanita Lake presented a review of Benzodiazepines and AD/ADHD therapies. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
- b. Public Comment: None
- c. Board Discussion: Sharon Weinstein asked if there is any death data related to this topic. Joanita Lake stated that they did not have any death data. Robyn Seely states we do not have access to the death data. Bryan Larson clarified that the Department of Health has this data; however, it is not something that Medicaid has access to. Neal Catalano asked if there is any communication going out to the providers on this topic. Robyn Seely provided information on the contact UDOH has with the U of U and the restriction program. Robyn Seely presented PA criteria for Concurrent Benzodiazepine and Stimulants. Jennifer Brinton inquired about the epileptic patients who are using a benzodiazepine as a rescue medication. Robyn Seely stated those cases will be excluded from the Concurrent Benzodiazepine and Stimulants PA. She also stated she would need to determine if Onfi would be excluded from the mutual exclusivity clause. Eric Cannon clarified the board discussion to say that the use of Benzodiazepines and Stimulants should only occur on an exception basis. Robyn Seely stated that there would be a grandfathering clause for members currently using these medications.
- **d. Board Action:** Eric Cannon motioned to adopt the Concurrent Benzodiazepine and Stimulants PA. Neal Catalano motioned to modify the motion to include treatment plan, DOPL check, and rationale and re-present at September DUB meeting. Kumar seconded. Unanimous approval.
- 6. **Public Meeting Adjourned:** Robyn Seely motioned to close the meeting. Neal Catalano seconded the motion. Unanimous Approval.
- 7. **The next meeting scheduled for Thursday, September 14, 2017** Tramadol and Codeine.